US 11,857,547 B2
Compositions and methods for opioid antagonist delivery
Haiyong Hugh Huang, Princeton Junction, NJ (US); and Manjunath S. Shet, White Plains, NY (US)
Assigned to Purdue Pharma L.P., Stamford, CT (US)
Filed by Purdue Pharma L.P., Stamford, CT (US)
Filed on May 9, 2023, as Appl. No. 18/195,142.
Application 18/195,142 is a continuation of application No. 16/674,755, filed on Nov. 5, 2019.
Claims priority of provisional application 62/820,582, filed on Mar. 19, 2019.
Claims priority of provisional application 62/756,322, filed on Nov. 6, 2018.
Prior Publication US 2023/0270741 A1, Aug. 31, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/395 (2006.01); A61K 31/485 (2006.01); A61K 47/02 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/485 (2013.01) [A61K 9/0019 (2013.01); A61K 47/02 (2013.01)] 7 Claims
 
1. A parenteral formulation comprising an aqueous solution comprising about 1.5 mg of nalmefene free base or an equivalent amount of a pharmaceutically acceptable salt thereof and about 0.5% to about 1.0% (w/v) of a parenterally acceptable adjuvant, wherein the formulation provides a mean time to maximum plasma concentration of nalmefene (Tmax) shorter than the mean time to maximum plasma concentration of nalmefene of a comparative formulation without the said adjuvant, post intramuscular or subcutaneous injection to a population of subjects,
wherein the adjuvant is magnesium chloride.